ImmunoPET and biodistribution with human epidermal growth factor receptor 3 targeting antibody Zr-89-RG7116
作者： Anton GT Terwisscha van Scheltinga , Marjolijn N Lub-de Hooge , Keelara Abiraj , Carolien P Schröder , Linda Pot
DOI: 10.4161/MABS.29097
关键词: Distribution (pharmacology) 、 Cancer research 、 In vivo 、 Metastatic breast cancer 、 Medicine 、 Biodistribution 、 Trastuzumab 、 Antibody 、 Cetuximab 、 Monoclonal antibody 、 Pathology
摘要: The humanized monoclonal antibody with high affinity for the human epidermal growth factor receptor (HER) 3, RG7116, is a glycoengineered, IgG1 class antibody. By labeling RG7116 zirconium-89 ((89)Zr) we aimed to visualize in vivo HER3 expression and study biodistribution of this tumor-bearing mice. Biodistribution (89)Zr-RG7116 was studied subcutaneously xenografted FaDu tumor cells (HER3-positive). Dose-dependency organ distribution specific uptake assessed by administering doses ranging from 0.05 10 mg/kg SCID/Beige analyzed at 24 144 h after injection. MicroPET imaging performed 1, 6 days injection 1.0 FaDu, H441, QG-56 Calu-1 xenografts varying expression. excised tumors were analyses showed dose- time-dependent tumors. highest observed dose group 27.5%ID/g tracer revealed H441 models an increase over time. data consistent microPET findings QG56 xenografts, which correlated levels. In conclusion, specifically accumulates expressing PET provides real-time non-invasive information about distribution, targeting
narcis.nl参考文章(29)
Lemoine Nr, Gullick Wj, Plowman Gd, Selden C, Prigent Sa, Hughes Cm, Expression of the c-erbB-3 protein in normal human adult and fetal tissues. Oncogene. ,vol. 7, pp. 1273- 1278 ,(1992)
健二郎 青儀, What's going on 乳癌 Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group(EBCTCG). Lancet. 2005; 365: 1687-717. PMID: 15894097.--早期乳癌に対する化学療法・内分泌療法が乳癌再発・15年生存率に及ぼす効果を示した論文:無作為化比較試験のメタアナリシス Mebio oncology. ,vol. 3, pp. 94- 98 ,(2006)
Wendie T. Anderson-Berg, Martin W. Brechbiel, Mette Strand, Otto A. Gansow, Saed Mirzadeh, Curtis L. Ruegg, Improved in vivo stability and tumor targeting of bismuth-labeled antibody. Cancer Research. ,vol. 50, pp. 4221- 4226 ,(1990)
Early Breast Cancer Trialists' Collaborative Group, None, Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials The Lancet. ,vol. 365, pp. 1687- 1717 ,(2005) , 10.1016/S0140-6736(05)66544-0
Dhara N. Amin, Marcia R. Campbell, Mark M. Moasser, The role of HER3, the unpretentious member of the HER family, in cancer biology and cancer therapeutics Seminars in Cell & Developmental Biology. ,vol. 21, pp. 944- 950 ,(2010) , 10.1016/J.SEMCDB.2010.08.007
Hugo JWL Aerts, Ludwig Dubois, Lars Perk, Peter Vermaelen, Guus AMS van Dongen, Bradly G Wouters, Philippe Lambin, Disparity Between In Vivo EGFR Expression and 89Zr-Labeled Cetuximab Uptake Assessed with PET The Journal of Nuclear Medicine. ,vol. 50, pp. 123- 131 ,(2009) , 10.2967/JNUMED.108.054312
José Baselga, Sandra M. Swain, Novel anticancer targets: revisiting ERBB2 and discovering ERBB3 Nature Reviews Cancer. ,vol. 9, pp. 463- 475 ,(2009) , 10.1038/NRC2656
Ami Citri, Yosef Yarden, EGF–ERBB signalling: towards the systems level Nature Reviews Molecular Cell Biology. ,vol. 7, pp. 505- 516 ,(2006) , 10.1038/NRM1962
Joan T. Garrett, Carlos L. Arteaga, Resistance to HER2-directed antibodies and tyrosine kinase inhibitors: mechanisms and clinical implications. Cancer Biology & Therapy. ,vol. 11, pp. 793- 800 ,(2011) , 10.4161/CBT.11.9.15045
Guus A.M.S. van Dongen, Maria J.W.D. Vosjan, Immuno-Positron Emission Tomography: Shedding Light on Clinical Antibody Therapy Cancer Biotherapy and Radiopharmaceuticals. ,vol. 25, pp. 375- 385 ,(2010) , 10.1089/CBR.2010.0812